相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future
Alain Beck et al.
EXPERT REVIEW OF PROTEOMICS (2019)
Synthesis, Characterization and in vitro Studies of a Cathepsin B-Cleavable Prodrug of the VEGFR Inhibitor Sunitinib
Claudia Karnthaler-Benbakka et al.
CHEMISTRY & BIODIVERSITY (2019)
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Jacob P. Laubach et al.
CLINICAL CANCER RESEARCH (2019)
A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy
Shujuan Xiong et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2019)
Toxicological profile and safety pharmacology of a single dose of fibroblast activation protein--based doxorubicin prodrug: in-vitro and in-vivo evaluation
Sichao Huang et al.
ANTI-CANCER DRUGS (2018)
Multifunctional Tumor-Targeting Cathepsin B-Sensitive Gemcitabine Prodrug Covalently Targets Albumin in Situ and Improves Cancer Therapy
Huicong Zhang et al.
BIOCONJUGATE CHEMISTRY (2018)
FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Emily Y. Jen et al.
CLINICAL CANCER RESEARCH (2018)
Design of pH-sensitive methotrexate prodrug-targeted curcumin nanoparticles for efficient dual-drug delivery and combination cancer therapy
Jiajiang Xie et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Synthesis and evaluation of water soluble pH sensitive poly (vinyl alcohol)-doxorubicin conjugates
Nahla Rahoui et al.
JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION (2018)
A pH-responsive prodrug delivery system self-assembled from acid-labile doxorubicin-conjugated amphiphilic pH-sensitive block copolymers
Xiangxuan Huang et al.
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2018)
Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study
Andrew Brenner et al.
NEURO-ONCOLOGY (2018)
Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models
Sushil Kumar et al.
TRANSLATIONAL ONCOLOGY (2018)
Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic
Joseph A. Reddy et al.
SCIENTIFIC REPORTS (2018)
A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy
Lingling Shan et al.
THERANOSTICS (2018)
Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy
Jianhua Zhu et al.
NANOSCALE (2018)
Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro
Nicolas Aubrey et al.
BIOCONJUGATE CHEMISTRY (2018)
Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo
Yan Huang et al.
CANCER COMMUNICATIONS (2018)
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma
Stephen M. F. Jamieson et al.
JCI INSIGHT (2018)
Legumain correlates with neuroblastoma differentiation and can be used in prodrug design
Min Zhang et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2018)
Reactive-Oxygen-Species-Responsive Drug Delivery Systems: Promises and Challenges
Gurusamy Saravanakumar et al.
ADVANCED SCIENCE (2017)
First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2017)
Strategies in the designing of prodrugs, taking into account the antiviral and anticancer compounds
Monika A. Lesniewska-Kowiel et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Synthesis and biological evaluation of hypoxia-activated prodrugs of SN-38
Chen Jin et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Prodrugs of triterpenoids and their derivatives
Meng Zhou et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy
Nicolas Joubert et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
A novel FAPa-basedZ-Gly-Pro epirubicin prodrug for improving tumor-targeting chemotherapy
Jun Wang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo
Ping Zhong et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents
Minfeng Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
William D. Tap et al.
LANCET ONCOLOGY (2017)
In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models
Jasmien Cornillie et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Gemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of Efficacy
Theodoros Karampelas et al.
MOLECULAR PHARMACEUTICS (2017)
Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
Hao Chen et al.
MOLECULES (2017)
A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model
Carla Hajj et al.
TRANSLATIONAL ONCOLOGY (2017)
An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo
Josef Mayr et al.
CHEMICAL SCIENCE (2017)
Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents
Masakazu Fukushima et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma
Shujing Liu et al.
ONCOTARGET (2017)
A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity
Dongyang Zhao et al.
BIOMATERIALS SCIENCE (2017)
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
Vasilios Liapis et al.
CANCER MEDICINE (2017)
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
Emil ter Veer et al.
SCIENTIFIC REPORTS (2017)
A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer
Steven S. Yu et al.
CLINICAL GENITOURINARY CANCER (2017)
A Tumor-Specific Cascade Amplification Drug Release Nanoparticle for Overcoming Multidrug Resistance in Cancers
Mingzhou Ye et al.
ADVANCED MATERIALS (2017)
Prodrugs in medicinal chemistry and enzyme prodrug therapies
Raoul Walther et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates
Alberto Dal Corso et al.
BIOCONJUGATE CHEMISTRY (2017)
Legumain-cleavable 4-arm poly(ethylene glycol)-doxorubicin conjugate for tumor specific delivery and release
Huicong Zhou et al.
ACTA BIOMATERIALIA (2017)
Targeted Chemo-Photodynamic Combination Platform Based on the DOX Prodrug Nanoparticles for Enhanced Cancer Therapy
Yumin Zhang et al.
ACS APPLIED MATERIALS & INTERFACES (2017)
Proteases in cancer drug delivery
Jennifer Vandooren et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Advancement in integrin facilitated drug delivery
Daniela Arosio et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Design and synthesis of peptide conjugates of phosphoramide mustard as prodrugs activated by prostate-specific antigen
Xinghua Wu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Self-assembly drug conjugates for anticancer treatment
Gaia Fumagalli et al.
DRUG DISCOVERY TODAY (2016)
10-Boronic acid substituted camptothecin as prodrug of SN-38
Lei Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Linkers Having a Crucial Role in Antibody-Drug Conjugates
Jun Lu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
Amy D. Guertin et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Controlled release strategy of paclitaxel by conjugating to matrix metalloproteinases-2 sensitive peptide
Changjiang Huang et al.
ONCOTARGET (2016)
Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy
Ewelina Piktel et al.
JOURNAL OF NANOBIOTECHNOLOGY (2016)
Surface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and Uses
Panoraia I. Siafaka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Self-Immolative Spacers: Kinetic Aspects, Structure-Property Relationships, and Applications
Ahmed Alouane et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer
Changde Zhang et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides
Anna Massaguer et al.
DALTON TRANSACTIONS (2015)
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
Marina Konopleva et al.
HAEMATOLOGICA (2015)
Somatostatin Receptor-Mediated Specific Delivery of Paclitaxel Prodrugs for Efficient Cancer Therapy
Meirong Huo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Polymer-Based Prodrugs: Improving Tumor Targeting and the Solubility of Small Molecule Drugs in Cancer Therapy
Sonja Dragojevic et al.
MOLECULES (2015)
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Elvin Blanco et al.
NATURE BIOTECHNOLOGY (2015)
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
Marina Konopleva et al.
HAEMATOLOGICA (2015)
First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma A Phase 2b Randomized Clinical Trial
Sant P. Chawla et al.
JAMA ONCOLOGY (2015)
Pharmacokinetic study of aldoxorubicin in patients with solid tumors
Monica M. Mita et al.
INVESTIGATIONAL NEW DRUGS (2015)
Curative Properties of Noninternalizing Antibody-Drug Conjugates Based on Maytansinoids
Elena Perrino et al.
CANCER RESEARCH (2014)
Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer
Stephen V. Liu et al.
CLINICAL CANCER RESEARCH (2014)
Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)
Guenter Emons et al.
GYNECOLOGIC ONCOLOGY (2014)
EPR: Evidence and fallacy
Joseph W. Nichols et al.
JOURNAL OF CONTROLLED RELEASE (2014)
A prodrug strategy based on chitosan for efficient intracellular anticancer drug delivery
Cheng Chen et al.
NANOTECHNOLOGY (2014)
A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity
Andrei Maksimenko et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Cathepsin B: Multiple roles in cancer
Neha Aggarwal et al.
PROTEOMICS CLINICAL APPLICATIONS (2014)
Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment
Ze Liu et al.
NATURE COMMUNICATIONS (2014)
The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo
Hiroshi Maeda et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Phase I Study of GRN1005 in Recurrent Malignant Glioma
Jan Drappatz et al.
CLINICAL CANCER RESEARCH (2013)
pH- and ion-sensitive polymers for drug delivery
Takayuki Yoshida et al.
EXPERT OPINION ON DRUG DELIVERY (2013)
Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)
Yan-Jun Zhong et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Stimuli-responsive nanocarriers for drug delivery
Simona Mura et al.
NATURE MATERIALS (2013)
Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis An experimental study
Li-Hua Shao et al.
CANCER (2012)
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer
Sandhya Girish et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Nazila Kamaly et al.
CHEMICAL SOCIETY REVIEWS (2012)
AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors
Joerg Engel et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Paclitaxel loaded nano-aggregates based on pH sensitive polyaspartamide amphiphilic graft copolymers
Kwangwon Seo et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2012)
Targeting Carcinoma-Associated Fibroblasts Within the Tumor Stroma With a Fibroblast Activation Protein-Activated Prodrug
W. Nathaniel Brennen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors
Razelle Kurzrock et al.
MOLECULAR CANCER THERAPEUTICS (2012)
ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage
Xiaohua Peng et al.
THERAPEUTIC DELIVERY (2012)
Prodrugs for improving tumor targetability and efficiency
Rubi Mahato et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo
Ki Young Choi et al.
BIOMATERIALS (2011)
A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
Mark J. McKeage et al.
BMC CANCER (2011)
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
Teemu T. Junttila et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes
L. Bildstein et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2011)
PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis
Ruchi Bansal et al.
JOURNAL OF CONTROLLED RELEASE (2011)
Hydrogen Peroxide Inducible DNA Cross-Linking Agents: Targeted Anticancer Prodrugs
Yunyan Kuang et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)
Conjugates of a Novel 7-Substituted Camptothecin with RGD-Peptides as αvβ3 Integrin Ligands: An Approach to Tumor-Targeted Therapy
Alma Dal Pozzo et al.
BIOCONJUGATE CHEMISTRY (2010)
The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3
Christopher P. Guise et al.
CANCER RESEARCH (2010)
Integrins in cancer: biological implications and therapeutic opportunities
Jay S. Desgrosellier et al.
NATURE REVIEWS CANCER (2010)
A Novel Antitumor Prodrug Platform Designed to Be Cleaved by the Endoprotease Legumain
Liron Stern et al.
BIOCONJUGATE CHEMISTRY (2009)
The original ‘magic bullet’ is 100 years old
Frank Heynick
BRITISH JOURNAL OF PSYCHIATRY (2009)
Prodrug Approaches for Enhancing the Bioavailability of Drugs with Low Solubility
Christaâ E. Müller
CHEMISTRY & BIODIVERSITY (2009)
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer
Leonard W. Seymour et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2009)
Clinical Pharmacokinetics and Exposure-Toxicity Relationship of a Folate-Vinca Alkaloid Conjugate EC145 in Cancer Patients
Jing Li et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Chemical and Enzymatic Stability of Amino Acid Prodrugs Containing Methoxy, Ethoxy and Propylene Glycol Linkers
Deepak Gupta et al.
MOLECULAR PHARMACEUTICS (2009)
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
L. Paz-Ares et al.
BRITISH JOURNAL OF CANCER (2008)
Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2
A. Regina et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Recent trends in targeted anticancer prodrug and conjugate design
Yashveer Singh et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer
Corey J. Langer et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review
Georgios V. Koukourakis et al.
MOLECULES (2008)
Prodrugs: design and clinical applications
Jarkko Rautio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma
Herbert Riechelmann et al.
ORAL ONCOLOGY (2008)
Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP)
Ralph Graeser et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate
Joseph A. Reddy et al.
CANCER RESEARCH (2007)
DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials
Felix Kratz
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Albumin-binding prodrugs of camptothecin and doxorubicin with an ala-leu-ala-leu-linker that are cleaved by cathepsin B: Synthesis and antitumor efficacy
Bjoern Schmid et al.
BIOCONJUGATE CHEMISTRY (2007)
Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel
Jayant J. Khandare et al.
BIOCONJUGATE CHEMISTRY (2006)
Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models
Y Chau et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms
WY Wu et al.
CANCER RESEARCH (2006)
Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies
O Aronov et al.
BIOCONJUGATE CHEMISTRY (2003)
Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics
JW Lee et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2002)
Targeted drug delivery to chemoresistant cells: Folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells. (vol 66, pg 5655, 2001)
J Liu et al.
JOURNAL OF ORGANIC CHEMISTRY (2002)
A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy
AN Vis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer
RS DiPaola et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia
DK Tack et al.
BONE MARROW TRANSPLANTATION (2001)
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation
H Gelderblom et al.
EUROPEAN JOURNAL OF CANCER (2001)
Synthesis and evaluation of pteroic acid-conjugated nitroheterocyclic phosphoramidates as folate receptor-targeted alkylating agents
G Steinberg et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Intravenous 5-fluorouracil versus oral doxifluridine as preoperative concurrent chemoradiation for locally advanced rectal cancer: Prospective randomized trials
NK Kim et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
